# Stannsoporfin With Light Therapy for Newborn Babies With Jaundice

> **NCT01887327** · PHASE2 · COMPLETED · sponsor: **InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company** · enrollment: 91 (actual)

## Conditions studied

- Jaundice, Neonatal
- Hyperbilirubinemia, Neonatal

## Interventions

- **PROCEDURE:** Phototherapy
- **DRUG:** Stannsoporfin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01887327
- **Lead sponsor:** InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-16
- **Primary completion:** 2016-03-22
- **Final completion:** 2016-03-22
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2020-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01887327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01887327, "Stannsoporfin With Light Therapy for Newborn Babies With Jaundice". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01887327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*